KKR & Co Inc vs Stryker Corporation — how do they compare? KKR & Co Inc trades at $91.07 (market cap $80.39B), while Stryker Corporation trades at $277.34 (market cap $106.24B). The key difference: Stryker Corporation is the larger of the two by market cap, and Stryker Corporation pays the higher dividend (1.27%). Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Stryker Corporation for 21 Days on average.
| KKR | SYK | |
|---|---|---|
Market Cap | $80.39B | $106.24B |
Volume | 6,517,705 | 2,982,001 |
Sector | Financials | Health |
52-Week High | $142.75 | $388.35 |
52-Week Low | $83.88 | $269.75 |
Typical Hold Time | 67 Days | 21 Days |
Enterprise Value | $2.95B | $117.70B |
Dividend Yield | 0.87% | 1.27% |
Signals from Pluang's Aura AI — not financial advice
KKR trades at $92.48, up 3.13% today, showing strong momentum after recent earnings beats. The stock faces bearish technical signals but maintains solid fundamentals with $19.21B revenue and $2.37B net income for 2025. Recent business developments include strategic joint ventures and asset sales, while analyst consensus remains overwhelmingly bullish with an average price target of $123.30.
KKR presents a compelling investment opportunity with strong earnings momentum and institutional support, though technical indicators suggest near-term caution. The company's diversified investment portfolio and active deal flow provide growth catalysts, balanced by market volatility risks and the cyclical nature of private equity returns.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →